{
"id":"mk19_a_np_t33",
"number":33,
"bookId":"np",
"title":{
"__html":"Medications Used in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ea5697",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 33. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_np_t33"
}
]
},
"Medications Used in the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f733ae",
"class":"col hd l",
"children":[
"Class/Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cdc4b",
"class":"col hd l",
"children":[
"Mechanism of Action"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d4c06",
"class":"cell txt l",
"children":[
"Phosphate binders"
]
},
" ",
{
"type":"p",
"hlId":"7fefc9",
"class":"cell txt li",
"children":[
"Noncalcium-based binders (e.g., sevelamer hydrochloride, sevelamer carbonate, lanthanum carbonate)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"3f5e1a",
"class":"cell txt li",
"children":[
"Iron-based (noncalcium) binders (e.g., sucroferric oxyhydroxide, ferric citrate)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e320d5",
"class":"cell txt li",
"children":[
"Calcium-based binders (e.g., calcium carbonate, calcium acetate)"
]
},
" ",
{
"type":"p",
"hlId":"418935",
"class":"cell txt li",
"children":[
"Aluminum-based binders (e.g., aluminum hydroxide)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19366c",
"class":"cell txt l",
"children":[
"Binds phosphate in GI tract before it can be absorbed; the binder-phosphate complex is excreted in the stool."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"73e482",
"class":"cell txt l",
"children":[
"Activated vitamin D agents (e.g., calcitriol, paricalcitol, doxercalciferol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8ec958",
"class":"cell txt l",
"children":[
"Inhibits PTH secretion via binding the vitamin D receptor on the parathyroid gland."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"782469",
"class":"cell txt l",
"children":[
"Calcimimetic agents (e.g., cinacalcet, etelcalcetide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d61f3",
"class":"cell txt l",
"children":[
"Inhibits PTH secretion via binding the calcium-sensing receptor, resulting in a morphology change and rendering the receptor more sensitive to the presence of calcium; for a given level of calcium, there is greater inhibition of PTH secretion."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Calcitriol = 1,25-dihydroxyvitamin D; GI = gastrointestinal; PTH = parathyroid hormone."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Preferred over calcium-based binders."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Aluminum-based phosphate binders are associated with aluminum toxicity and should no longer be used in patients with chronic kidney disease."
]
]
}